{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:43:58Z","timestamp":1764225838508,"version":"3.46.0"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To report a case with concurrent myasthenia gravis (MG) and thyroid eye disease (TED) showing response to rituximab (RTX) through both clinical evaluation and quantitative MRI assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 31-year-old female patient with refractory ocular symptoms from concurrent MG and TED received RTX after failing multiple conventional treatments. Treatment response was evaluated through clinical scores and quantitative T2 mapping of extraocular muscles (EOMs) before and after RTX administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following RTX treatment, the patient achieved corticosteroid-free remission by six months post-RTX, with Myasthenia Gravis Activities of Daily Living score decreasing from 5 to 0, complete resolution of ptosis, and improvement in ocular motility and exophthalmos. Quantitative T2 mapping demonstrated significant reductions in T2 relaxation times (10.6%-20.9%) across all EOM regions of interest, with decreased standard deviations indicating restored tissue homogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case suggests potential therapeutic benefit of RTX for refractory ocular symptoms in concurrent MG and TED. Quantitative T2 mapping revealed pathologically elevated values that normalized post-treatment, providing preliminary objective evidence of treatment response. As a single case, the relative contributions of MG versus TED pathology cannot be definitively separated. Integrating clinical assessment with quantitative T2 mapping may offer an objective approach for monitoring treatment response in such complex dual autoimmune disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1717260","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:50Z","timestamp":1764225050000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rituximab for refractory ocular symptoms in myasthenia gravis with thyroid eye disease: a case report with quantitative MRI assessment"],"prefix":"10.3389","volume":"16","author":[{"given":"Dingxian","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baitong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chong","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Hibert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongbo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianying","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231163819","article-title":"Immunotherapy for ocular myasthenia gravis: an observational study in Japan","volume":"16","author":"Narita","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001339","article-title":"Thyroid eye disease and ocular myasthenia gravis","volume":"38","author":"Shabto","year":"2025","journal-title":"Curr Opin Neurol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1186\/s12883-019-1573-2","article-title":"Understanding side effects of therapy for myasthenia gravis and their impact on daily life","volume":"19","author":"Bacci","year":"2019","journal-title":"BMC Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51492","article-title":"Drug-refractory myasthenia gravis: Clinical characteristics, treatments, and outcome","volume":"9","author":"Cort\u00e9s-Vicente","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive therapies in myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-024-03025-z","article-title":"Comparative effectiveness and safety of intravenous methylprednisolone and tacrolimus monotherapy in ocular myasthenia gravis with unsatisfactory prednisone responses: a retrospective study","volume":"19","author":"Zhang","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2887","article-title":"Efficacy and safety of rituximab for new-onset generalized myasthenia gravis: the RINOMAX randomized clinical trial","volume":"79","author":"Piehl","year":"2022","journal-title":"JAMA Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e220189","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a Consensus Statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578558","article-title":"Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series","volume":"401","author":"He","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/life14101223","article-title":"Mechanisms of resistance to rituximab used for the treatment of autoimmune blistering diseases","volume":"14","author":"Popa","year":"2024","journal-title":"Life (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1016\/j.jid.2021.01.031","article-title":"Rituximab and corticosteroid effect on desmoglein-specific B cells and desmoglein-specific T follicular helper cells in pemphigus","volume":"141","author":"Maho-Vaillant","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.29803","article-title":"Feasibility of qualitative evaluation and quantitative T2 mapping of peripheral nerves and muscles using GRAPPATINI","volume":"62","author":"Lu","year":"2025","journal-title":"J Magn Reson Imaging"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.27754","article-title":"Quantitative MRI T2 mapping is able to assess tissue quality after reparative and regenerative treatments of osteochondral lesions of the talus","volume":"54","author":"Rizzo","year":"2021","journal-title":"J Magn Reson Imaging"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1717260\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:30:54Z","timestamp":1764225054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1717260\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":18,"alternative-id":["10.3389\/fimmu.2025.1717260"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1717260","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"article-number":"1717260"}}